


What is claimed is:

1. A compound of the formula (I)



wherein

R^1 is hydrogen, OH, NH_2 , lower-alkoxy-carbonyl, aryl-lower-alkoxy-carbonyl, aryloxy-carbonyl, lower-alkyl-carbonyl, aryl-carbonyl, or halogen substituted lower-alkoxy-carbonyl;

R^2 , R^3 and R^4 independently from each other are selected from the group consisting of hydrogen, halogen, hydroxy, carboxy-lower-alkyl-NH, carbamoyl-lower-alkyl-NH, lower-alkoxy-carbonyl-lower-alkyl-NH, hydroxy-cycloalkyl-oxy, dihydroxy-cycloalkyl-oxy, aryl, aryloxy, aryl-NH, aryl-lower-alkyl-NH, aryl-lower-alkyl- SO_2 -NH, aryl-lower-alkoxy-carbonyl-NH, aryl-lower-alkyl-NH-carbonyl-NH, heteroaryloxy, heteroaryl-lower-alkyl-NH, lower-alkoxy, and lower-alkoxy substituted with hydroxy, carboxy, carbamoyl, carbamimidoyl, CF_3 , aryl, heteroaryl, lower-alkyl-carbamoyl, lower-alkoxy-carbonyl, aryl-carbamoyl, lower-alkoxy-lower-alkyl-carbamoyl, heterocyclyl-lower-alkyl-carbamoyl, or $\text{N}(\text{lower-alkyl})_2$ -lower-alkyl-carbamoyl;

R^5 is lower-alkyl or cycloalkyl, or, if X is O or NR^{12} , R^5 is lower alkyl, cycloalkyl or hydrogen;

R^6 is hydrogen, lower-alkyl, or fluoro-lower-alkyl;

Y is N or $\text{C}-\text{R}^{11}$;

R⁷, R⁸, R⁹, R¹⁰ and R¹¹ independently from each other are selected from the group consisting of hydrogen, hydroxy, halogen, amino, lower-alkyl-amino, di-lower-alkyl-amino, lower-alkyl-carbonyl-amino, NO₂, fluoro-lower-alkyl, lower-alkoxy, hydroxy-lower-alkoxy, fluoro-lower-alkoxy, lower-alkinyl, hydroxy-lower-alkinyl, aryl, aryl-lower-alkoxy, aryloxy, aryloxy-lower-alkoxy, heterocyclyl, heterocyclyloxy, lower-alkoxy-carbonyl-lower-alkoxy, carbamoyl-lower-alkoxy, carboxy-lower-alkoxy, cycloalkyloxy, heteroaryl, amino-lower-alkoxy, lower-alkyl-amino-lower-alkoxy, and di-lower-alkyl-amino-lower-alkoxy, lower-alkyl-carbonyl-amino-lower-alkyl, HO-N=CH, HCO, fluoro-lower-alkyl-SO₂-O, (lower-alkoxy)₂₋₄, CH(lower-alkoxy)₂, hydroxy-chloro-lower-alkoxy, aryl-lower-alkoxy-lower-alkoxy, aryl-NH, aryl-NH-lower-alkyl, aryl-lower-alkyl-carbonyl-NH, heterocyclyl-lower-alkyl, heterocyclyl-carbonyl, heterocyclyl-lower-alkoxy, lower-alkyl-carbamoyl, fluoro-lower-alkyl-carbamoyl, cycloalkyl-carbamoyl, cycloalkyl-lower-alkyl-carbamoyl, di-lower-alkyl-carbamoyl, lower-alkoxy-lower-alkyl-carbamoyl, di-lower-alkyl-carbamoyl-lower-alkoxy, heteroaryloxy, heteroaryl-lower-alkoxy, amino-lower-alkyl, lower-alkyl, hydroxy-lower-alkyl, cycloalkyl, cycloalkyl-lower-alkoxy, and cycloalkyl-lower-alkoxy substituted with lower-alkyl;

or

R⁸ and R⁹ or R⁸ and R⁷ are bound to each other to form a ring together with the carbon atoms to which they are attached and R⁸ and R⁹ together or R⁸ and R⁷ together are -O-CH₂-O-, -O-CH₂-CO-NH-, -O-CH₂-CH₂-CH₂-, -CH=CH-CH=CH-, or -CH=CH-CH=CH- substituted with lower-alkyl or lower-alkoxy, and R¹⁰, R¹¹ and R⁷ or R⁹ respectively are as defined above;

X is O, S, NR¹², or SO₂;

R¹² is hydrogen, lower-alkyl, or lower-alkyl-carbonyl;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein

R¹ is hydrogen, OH, NH₂, lower-alkoxy-carbonyl, aryl-lower-alkoxy-carbonyl, aryloxy-carbonyl, lower-alkyl-carbonyl, aryl-carbonyl, or halogen substituted lower-alkoxy-carbonyl;

R², R³ and R⁴ independently from each other are selected from the group consisting of hydrogen, halogen, hydroxy, and lower-alkoxy, and lower-alkoxy substituted with hydroxy, carboxy or carbamoyl;

R⁵ is lower-alkyl or cycloalkyl, or, if X is O or NR¹², R⁵ is lower alkyl, cycloalkyl or hydrogen;

R⁶ is hydrogen, lower-alkyl, or fluoro-lower-alkyl;

Y is N or C-R¹¹;

R⁷, R⁸, R⁹, R¹⁰ and R¹¹ independently from each other are selected from the group consisting of hydrogen, hydroxy, halogen, amino, lower-alkyl-amino, di-lower-alkyl-amino, lower-alkyl-carbonyl-amino, NO₂, fluoro-lower-alkyl, lower-alkoxy, hydroxy-lower-alkoxy, fluoro-lower-alkoxy, lower-alkinyl, hydroxy-lower-alkinyl, aryl, aryl-lower-alkoxy, aryloxy, aryloxy-lower-alkoxy, heterocyclyl, heterocyclyloxy, lower-alkoxy-carbonyl-lower-alkoxy, carbamoyl-lower-alkoxy, carboxy-lower-alkoxy, cycloalkyloxy, heteroaryl, amino-lower-alkoxy, lower-alkyl-amino-lower-alkoxy, and di-lower-alkyl-amino-lower-alkoxy,

or

R⁸ and R⁹ or R⁸ and R⁷ are bound to each other to form a ring together with the carbon atoms to which they are attached and R⁸ and R⁹ together or R⁸ and R⁷ together are -O-CH₂-O-, -O-CH₂-CO-NH-, -O-CH₂-CH₂-CH₂-, -CH=CH-CH=CH-, or -CH=CH-CH=CH- substituted with lower-alkyl or lower-alkoxy, and R¹⁰, R¹¹ and R⁷ or R⁹ respectively are as defined above;

X is O, S, NR¹², or SO₂;

R¹² is hydrogen, lower-alkyl, or lower-alkyl-carbonyl;

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1, wherein R¹ is hydrogen, OH, NH₂, or lower-alkoxy-carbonyl.

4. The compound according to claim 1, wherein R¹ is hydrogen, OH, or lower-alkoxy-carbonyl.

5. The compound according to claim 1, wherein R¹ is hydrogen, OH, or ethoxycarbonyl.

6. The compound according to claim 1, wherein R¹ is hydrogen.

7. The compounds according to any of claims 1 – 6, wherein R^2 , R^3 and R^4 independently from each other are hydrogen or halogen.
8. The compound according to claim 1, wherein R^2 , R^3 and R^4 are hydrogen.
9. The compound according to claim 1, wherein R^2 and R^4 are hydrogen.
10. The compound according to claim 1, wherein R^3 is hydrogen, halogen, hydroxy, carboxy-lower-alkyl-NH, carbamoyl-lower-alkyl-NH, lower-alkoxy-carbonyl-lower-alkyl-NH, hydroxy-cycloalkyl-oxy, dihydroxy-cycloalkyl-oxy, aryl, aryloxy, aryl-NH, aryl-lower-alkyl-NH, aryl-lower-alkyl-SO₂-NH, aryl-lower-alkoxy-carbonyl-NH, aryl-lower-alkyl-NH-carbonyl-NH, heteroaryloxy, heteroaryl-lower-alkyl-NH, lower-alkoxy, or lower-alkoxy substituted with hydroxy, carboxy, carbamoyl, carbamimidoyl, CF₃, aryl, heteroaryl, lower-alkyl-carbamoyl, lower-alkoxy-carbonyl, aryl-carbamoyl, lower-alkoxy-lower-alkyl-carbamoyl, heterocyclyl-lower-alkyl-carbamoyl, or N(lower-alkyl)₂-lower-alkyl-carbamoyl.
11. The compound according to claim 1, wherein R^3 is hydrogen, halogen, carboxy-lower-alkyl-NH, aryl-lower-alkyl-NH, heteroaryl-lower-alkyl-NH, lower-alkoxy, or lower-alkoxy substituted with carbamoyl, heteroaryl, or lower-alkoxy-lower-alkyl-carbamoyl.
12. The compound according to claim 1, wherein R^3 is hydrogen, fluorine, carbamoylmethoxy, (2-methoxy-ethylcarbamoyl)-methoxy, pyridin-2-yl-methoxy, benzylamino, carboxymethyl-amino, or pyridin-2-ylmethyl-amino.
13. The compound according to claim 1, wherein X is O.
14. The compound according to claim 1, wherein R^5 is lower-alkyl.
15. The compound according to claim 1, wherein R^5 is methyl or ethyl.
16. The compound according to claim 1, wherein R^6 is hydrogen, methyl, or CF₃.
17. The compound according to claim 1, wherein R^6 is hydrogen.

18. The compound according to claim 1, wherein Y is C-R¹¹ and R⁷, R⁸, R⁹, R¹⁰ and R¹¹ independently from each other are selected from the group consisting of hydrogen, hydroxy, halogen, di-lower-alkyl-amino, lower-alkyl-carbonyl-amino, NO₂, fluoro-lower-alkyl, lower-alkoxy, hydroxy-lower-alkoxy, fluoro-lower-alkoxy, aryl, aryl-lower-alkoxy, aryloxy, aryloxy-lower-alkoxy, heterocyclyl, heterocyclyloxy, lower-alkoxy-carbonyl-lower-alkoxy, carbamoyl-lower-alkoxy, carboxy-lower-alkoxy, cycloalkyloxy, heteroaryl, and di-lower-alkyl-amino-lower-alkoxy.
19. The compound according to claim 1, wherein Y is C-R¹¹ and R⁷, R⁸, R⁹, R¹⁰ and R¹¹ independently from each other are selected from the group consisting of hydrogen, halogen, lower-alkoxy, and pyridyl.
20. The compound according to claim 1, wherein Y is C-R¹¹ and R⁷, R⁸, R⁹, R¹⁰ and R¹¹ independently from each other are selected from the group consisting of hydrogen, fluoro, bromo, methoxy, and pyridyl.
21. The compound according to claim 1, wherein Y is C-R¹¹, R⁸ and R⁹ or R⁸ and R⁷ are bound to each other to form a ring together with the carbon atoms to which they are attached and R⁸ and R⁹ together or R⁸ and R⁷ together are -O-CH₂-O-, -O-CH₂-CO-NH-, -O-CH₂-CH₂-CH₂-, -CH=CH-CH=CH-, or -CH=CH-CH=CH- substituted with lower-alkyl or lower-alkoxy, and R¹⁰, R¹¹ and R⁷ or R⁹ respectively are hydrogen.
22. The compound according to claim 1, wherein Y is C-R¹¹ and R⁷, R⁸, R⁹, R¹⁰ and R¹¹ independently from each other are selected from the group consisting of hydrogen, halogen, lower-alkoxy and heteroaryl.
23. The compound according to claim 1, wherein Y is C-R¹¹, R⁷ is halogen, R⁸ is hydrogen, R⁹ is lower-alkoxy, heteroaryl or heteroaryl-lower-alkoxy, R¹⁰ is hydrogen and R¹¹ is hydrogen or halogen.
24. The compound according to claim 1, wherein Y is C-R¹¹, R⁷ is fluorine, R⁸ is hydrogen, R⁹ is methoxy, pyridin-3-yl, 5-amino-pyridin-2-yl, 6-amino-pyridin-3-yl,

pyridin-2-ylmethoxy, or 2-amino-pyrimidin-5-yl, R¹⁰ is hydrogen and R¹¹ is hydrogen or fluorine.

25. The compound according to claim 1, selected from the group consisting of
(S)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-phenyl-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-[Amino-(4-{[2-(2-fluoro-4-methoxy-phenyl)-2-methoxy-acetyl-amino]-methyl}-phenyl)-methylene]-carbamic acid ethyl ester,
(RS)-2-(2-Fluoro-4-methoxy-phenyl)-N-[4-(N-hydroxycarbamimidoyl)-benzyl]-2-methoxy-acetamide,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-fluoro-3'-methoxy-biphenyl-4-yl)-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-4-pyridin-3-yl-phenyl)-2-methoxy-acetamide hydrochloride, and
(RS)-2-(4-Bromo-2,6-difluoro-phenyl)-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride,
or a pharmaceutically acceptable salt thereof.

26. The compound according to claim 1, selected from the group consisting of
(RS)-N-(4-Carbamimidoyl-2-carbamoylmethoxy-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
(RS)-N-{4-Carbamimidoyl-2-[(2-methoxy-ethylcarbamoyl)-methoxy]-benzyl}-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
(RS)-N-[4-Carbamimidoyl-2-(pyridin-2-ylmethoxy)-benzyl]-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-2-[4-(2-Amino-pyrimidin-5-yl)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-pyridin-3-yl-phenyl)-2-ethoxy-acetamide hydrochloride,

(RS)-2-[4-(5-Amino-pyridin-2-yl)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-(2-[4-(6-Amino-pyridin-3-yl)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamidoyl-benzyl)-2-[2,6-difluoro-4-(pyridin-2-ylmethoxy)-phenyl]-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(2-Benzylamino-4-carbamimidoyl-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide acetate,
 (RS)-(5-Carbamidoyl-2-[[2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetylamino]-methyl]-phenylamino)-acetic acid acetate,
 (RS)-(4-Carbamidoyl-2-carbamoylmethoxy-benzyl)-2-[2,6-difluoro-4-(pyridin-2-ylmethoxy)-phenyl]-2-ethoxy-acetamide hydrochloride,
 (RS)-2-[4-(6-Amino-pyridin-3-yl)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-2,6-difluoro-benzyl)-2-ethoxy-acetamide acetate, and
 (RS)-{4-Carbamidoyl-2-[(pyridin-2-ylmethyl)-amino]-benzyl}-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
 or a pharmaceutically acceptable salt thereof.

27. The compound according to claim 1, selected from the group consisting of
 (S)-N-(4-Carbamidoyl-benzyl)-2-methoxy-2-phenyl-acetamide hydrochloride,
 (R)-N-(4-Carbamidoyl-benzyl)-2-methoxy-2-phenyl-acetamide hydrochloride,
 (RS)-2-(4-Benzoyloxy-phenyl)-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamidoyl-benzyl)-2-methoxy-2-(4-phenoxy-phenyl)-acetamide hydrochloride,
 (RS)-N-(4-Carbamidoyl-benzyl)-2-methoxy-2-(3-phenoxy-phenyl)-acetamide hydrochloride,
 (RS)-N-(4-Carbamidoyl-benzyl)-2-ethoxy-2-phenyl-acetamide hydrochloride,
 (RS)-N-(4-Carbamidoyl-benzyl)-2-(2-fluoro-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-2-(3-Benzoyloxy-phenyl)-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamidoyl-benzyl)-2-(3-hydroxy-phenyl)-2-methoxy-acetamide hydrochloride, and

(RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-(3-nitro-phenyl)-acetamide hydrochloride, or
a pharmaceutically acceptable salt thereof.

28. The compound according to claim 1, selected from the group consisting of
(RS)-2-Biphenyl-4-yl-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide hydrochloride,
(RS)-2-Benzo[1,3]dioxol-5-yl-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide hydrochloride,
(RS)-2-Benzo[1,3]dioxol-5-yl-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-[5-ethoxy-2-fluoro-3-(1-methyl-piperidin-4-yloxy)-phenyl]-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-[Amino-(4-{[2-(2-fluoro-4-methoxy-phenyl)-2-methoxy-acetyl-amino]-methyl}-phenyl)-methylene]-carbamic acid ethyl ester,
(RS)-2-(2-Fluoro-4-methoxy-phenyl)-N-[4-(N-hydroxycarbamimidoyl)-benzyl]-2-methoxy-acetamide,
(RS)-2-(2-Fluoro-4-methoxy-phenyl)-N-[4-(N-aminocarbamimidoyl)-benzyl]-2-methoxy-acetamide,
(RS)-{5-[(4-Carbamimidoyl-benzylcarbamoyl)-methoxy-methyl]-2-methoxy-phenoxy}-acetic acid methyl ester hydrochloride, and
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-carbamoylmethoxy-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride, or
a pharmaceutically acceptable salt thereof.

29. The compound according to claim 1, selected from the group consisting of
(RS)-{5-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-2-methoxy-phenoxy}-acetic acid ethyl ester hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-carbamoylmethoxy-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
(RS)-{5-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-2-methoxy-phenoxy}-acetic acid,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-ethoxy-2-(4-ethoxy-phenyl)-acetamid

hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-[4-(1-methyl-piperidin-4-yloxy)-phenyl]-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-3,3,3-trifluoro-2-methoxy-2-phenyl-propionamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-4,5-dimethoxy-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-isopropoxy-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(4-cyclopentyloxy-phenyl)-2-methoxy-acetamide hydrochloride, and
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(4-isopropoxy-phenyl)-2-methoxy-acetamide hydrochloride, or
 a pharmaceutically acceptable salt thereof.

30. The compound according to claim 1, selected from the group consisting of
 (RS)-{4-[(4-Carbamimidoyl-benzylcarbamoyl)-methoxy-methyl]-phenoxy}-acetic acid methyl ester hydrochloride,
 (RS)-{4-[(4-Carbamimidoyl-benzylcarbamoyl)-methoxy-methyl]-phenoxy}-acetic acid,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-[3-(tetrahydro-pyran-4-yloxy)-phenyl]-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3,5-diethoxy-2-fluoro-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[5-ethoxy-2-fluoro-4-(2-hydroxy-ethoxy)-phenyl]-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3,4-diethoxy-2-fluoro-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-2-fluoro-benzyl)-2-(2-fluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-3-fluoro-benzyl)-2-(2-fluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-2-(2,4-Bis-trifluoromethyl-phenyl)-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide hydrochloride, and

(RS)-N-[4-(N-Hydroxycarbamimidoyl)-benzyl]-2-(2-hydroxy-4-methoxy-phenyl)-2-methoxy-acetamide,
or a pharmaceutically acceptable salt thereof.

31. The compound according to claim 1, selected from the group consisting of
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-hydroxy-4-methoxy-phenyl)-2-methoxy-acetamide acetate,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-5-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,3-difluoro-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-2-(4-Bromo-2-fluoro-phenyl)-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide hydrochloride,
(RS)-2-(4-Bromo-2-fluoro-phenyl)-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride,
(RS)-2-(4-Bromo-2-fluoro-phenyl)-N-(4-carbamimidoyl-benzyl)-2-propoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-4-trifluoromethyl-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-[4-(2-hydroxy-ethoxy)-phenyl]-2-methoxy-acetamide hydrochloride, and
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(4-dimethylamino-phenyl)-2-methoxy-acetamide hydrochloride, or
a pharmaceutically acceptable salt thereof.

32. The compound according to claim 1, selected from the group consisting of
(RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-(4-pyrrolidin-1-yl-phenyl)-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-chloro-phenyl)-2-methoxy-acetamide hydrochloride,

(RS)-2-(4-Acetylamino-phenyl)-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-(4-trifluoromethoxy-phenyl)-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(4-imidazol-1-yl-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-(6-methoxy-naphthalen-2-yl)-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-(4-morpholin-4-yl-phenyl)-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-(2-morpholin-4-yl-phenyl)-acetamide hydrochloride, and
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[4-(3-dimethylamino-propoxy)-phenyl]-2-methoxy-acetamide hydrochloride, or
 a pharmaceutically acceptable salt thereof.

33. The compound according to claim 1, selected from the group consisting of
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(4'-dimethylamino-3-fluoro-biphenyl-4-yl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-fluoro-4'-methoxy-biphenyl-4-yl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-fluoro-2'-methoxy-biphenyl-4-yl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-fluoro-biphenyl-4-yl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-fluoro-3'-methoxy-biphenyl-4-yl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,2-dimethyl-chroman-6-yl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
 (RS)-2-Ethoxy-2-(2-fluoro-4-methoxy-phenyl)-N-[4-(N-hydroxycarbamimidoyl)-benzyl]-acetamide,
 (RS)-4-[3-(3-Cyclopentyloxy-4-methoxy-phenyl)-3-methoxy-2-oxo-propylamino]-

benzamidine hydrochloride, and
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-chloro-4-methoxy-phenyl)-2-methoxy-acetamide
hydrochloride, or
a pharmaceutically acceptable salt thereof.

34. The compound selected from claim 1, selected from the group consisting of
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-
acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-4-methoxy-phenyl)-2-propoxy-acetamide
hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-naphthalen-1-yl-propionamide
hydrochloride,
(RS)-2-(4-Bromo-2,6-difluoro-phenyl)-N-(4-carbamimidoyl-benzyl)-2-methoxy-
acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-4-isopropoxy-phenyl)-2-methoxy-
acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-4-isobutoxy-phenyl)-2-methoxy-
acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-{2-fluoro-4-[2-(4-fluoro-phenyl)-ethoxy]-phenyl}-
2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-4-pyridin-3-yl-phenyl)-2-methoxy-
acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-4-pyridin-4-yl-phenyl)-2-methoxy-
acetamide hydrochloride, and
(RS)-2-(5-Bromo-2-fluoro-phenyl)-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide
hydrochloride, or
a pharmaceutically acceptable salt thereof.

35. The compound according to claim 1, selected from the group consisting of
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(4-fluoro-biphenyl-3-yl)-2-methoxy-acetamide
hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-5-methyl-phenyl)-2-methoxy-acetamide
hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-5-trifluoromethyl-phenyl)-2-methoxy-

acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-6-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-6-hydroxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-dimethylamino-2-phenyl-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-methylamino-2-phenyl-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-methylsulfanyl-2-phenyl-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-ethylsulfanyl-2-phenyl-acetamide hydrochloride,
and
(RS)-N-(4-Carbamimidoyl-benzyl)-2-methanesulfonyl-2-phenyl-acetamide hydrochloride,
or
a pharmaceutically acceptable salt thereof.

36. The compound according to claim 1, selected from the group consisting of
(RS)-2-Amino-N-(4-carbamimidoyl-benzyl)-2-phenyl-acetamide hydrochloride,
(RS)-2-Acetyl-amino-N-(4-carbamimidoyl-benzyl)-2-phenyl-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-[2-fluoro-4-(2-phenoxy-ethoxy)-phenyl]-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-pyridin-2-yl-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-phenyl-propionamide hydrochloride,
(RS)-2-(4-Bromo-2,6-difluoro-phenyl)-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride,
N-(4-Carbamimidoyl-benzyl)-2-[2-fluoro-6-(2-hydroxy-ethoxy)-phenyl]-2-methoxy-acetamide hydrochloride, and
N-(4-Carbamimidoyl-benzyl)-2-(2-carbamoylmethoxy-6-fluoro-phenyl)-2-methoxy-acetamide hydrochloride,
or a pharmaceutically acceptable salt thereof.

37. The compound according to claim 1, selected from the group consisting of
(RS)-2-Biphenyl-4-yl-N-(4-carbamimidoyl-benzyl)-2-ethoxy-propionamide hydrochloride,
(RS)-2-[3-(1-Benzenesulfonyl-piperidin-4-yloxy)-5-ethoxy-2-fluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide hydrochloride,

(RS)-N-(4-Carbamimidoyl-benzyl)-2-[5-ethoxy-2-fluoro-3-(1-methanesulfonyl-piperidin-4-yloxy)-phenyl]-2-methoxy-acetamide hydrochloride,
 (RS)-2-[3-(1-Acetyl-piperidin-4-yloxy)-5-ethoxy-2-fluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide hydrochloride,
 (RS)-2-[3-(1-Benzoyl-piperidin-4-yloxy)-5-ethoxy-2-fluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-2-chloro-benzyl)-2-(2-fluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-2-chloro-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-2-chloro-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-2-chloro-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride, and
 (RS)-N-[3-Chloro-4-(N-hydroxycarbamimidoyl)-benzyl]-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide, or
 a pharmaceutically acceptable salt thereof.

38. The compound according to claim 1, selected from the group consisting of
 (RS)-N-(4-Carbamimidoyl-3-chloro-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide acetate,
 (RS)-2-(4-Bromo-2,6-difluoro-phenyl)-N-(4-carbamimidoyl-2-methoxy-benzyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-2-methoxy-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-2-phenoxy-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-2-o-tolyloxy-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
 (RS)-N-[4-Carbamimidoyl-2-(4-fluoro-phenoxy)-benzyl]-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
 (RS)-N-[4-Carbamimidoyl-2-(pyridin-3-yloxy)-benzyl]-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide acetic acid,
 (RS)-N-[4-Carbamimidoyl-2-(5-nitro-pyridin-2-yloxy)-benzyl]-2-ethoxy-2-(2-fluoro-4-

methoxy-phenyl)-acetamide hydrochloride,
(RS)-N-[2-(5-Amino-pyridin-2-yloxy)-4-carbamimidoyl-benzyl]-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride, and
(RS)-N-(5-Carbamidoyl-biphenyl-2-ylmethyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride, or
a pharmaceutically acceptable salt thereof.

39. The compound according to claim 1, selected from the group consisting of
(RS)-(5-Carbamidoyl-2-{{2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetyl-amino}-methyl}-phenoxy)-acetic acid ethyl ester hydrochloride,
(RS)-N-(4-Carbamidoyl-2-carbamoylmethoxy-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
(RS)-N-(4-Carbamidoyl-2-isopropoxy-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
(RS)-N-[4-Carbamidoyl-2-(2-hydroxy-ethoxy)-benzyl]-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
2-(5-Carbamidoyl-2-{{2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetyl-amino}-methyl}-phenoxy)-N-isopropyl-2-phenyl-acetamide hydrochloride,
(RS)-(5-Carbamidoyl-2-{{2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetyl-amino}-methyl}-phenoxy)-acetic acid,
(RS)-(S)-2-(5-Carbamidoyl-2-{{2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetyl-amino}-methyl}-phenoxy)-propionic acid ethyl ester hydrochloride,
((RS)-S)-2-(5-Carbamidoyl-2-{{2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetyl-amino}-methyl}-phenoxy)-propionamide hydrochloride,
(RS)-(R)-2-(5-Carbamidoyl-2-{{2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetyl-amino}-methyl}-phenoxy)-propionic acid ethyl ester hydrochloride, and
(RS)-(R)-2-(5-Carbamidoyl-2-{{2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetyl-amino}-methyl}-phenoxy)-propionamide hydrochloride, or
a pharmaceutically acceptable salt thereof.

40. The compound according to claim 1, selected from the group consisting of
(RS)-N-(4-Carbamidoyl-2-carbamoylmethoxy-benzyl)-2-(2-fluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamidoyl-2-phenoxy-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-

ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-2-methoxy-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-2-carbamoylmethoxy-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-[4-Carbamimidoyl-2-(2-fluoro-benzyloxy)-benzyl]-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-[4-Carbamimidoyl-2-(5-chloro-2-fluoro-benzyloxy)-benzyl]-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-{4-Carbamimidoyl-2-[(2-methoxy-ethylcarbamoyl)-methoxy]-benzyl}-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-{4-Carbamimidoyl-2-[(2-morpholin-4-yl-ethylcarbamoyl)-methoxy]-benzyl}-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-{4-Carbamimidoyl-2-[(2-diethylamino-ethylcarbamoyl)-methoxy]-benzyl}-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride, and
 (RS)-N-[4-Carbamimidoyl-2-([1,2,4]oxadiazol-3-ylmethoxy)-benzyl]-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride, or
 a pharmaceutically acceptable salt thereof.

41. The compound according to claim 1, selected from the group consisting of
 (RS)-N-(4-Carbamimidoyl-2-carbamimidoylmethoxy-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-[2-(1H-Benzoimidazol-2-ylmethoxy)-4-carbamimidoyl-benzyl]-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-[4-Carbamimidoyl-2-((1S,3R,4S)-3,4-dihydroxy-cyclopentyloxy)-benzyl]-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 a mixture of (RS) and (SR)-N-[4-Carbamimidoyl-2-((1RS,2RS)-2-hydroxy-cyclopentyloxy)-benzyl]-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-2-carbamoylmethoxy-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-2-methylcarbamoylmethoxy-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-[4-Carbamimidoyl-2-(isopropylcarbamoyl-methoxy)-benzyl]-2-(2,6-difluoro-4-

methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-N-{4-Carbamimidoyl-2-[(4-fluoro-phenylcarbamoyl)-methoxy]-benzyl}-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-N-[4-Carbamimidoyl-2-(pyridin-2-ylmethoxy)-benzyl]-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride, and
(RS)-N-[4-Carbamimidoyl-2-(2,2,2-trifluoro-ethoxy)-benzyl]-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride, or
a pharmaceutically acceptable salt thereof.

42. The compound according to claim 1, selected from the group consisting of
(RS)-N-[4-Carbamimidoyl-2-(pyridin-3-ylmethoxy)-benzyl]-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-N-[4-Carbamimidoyl-2-(pyridin-4-ylmethoxy)-benzyl]-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-hydroxy-phenyl)-2-ethoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-4-(2-morpholin-4-yl-ethoxy)-phenyl]-2-ethoxy-acetamide dihydrochloride,
(RS)-{[4-({2-[2,6-Difluoro-4-(2-morpholin-4-yl-ethoxy)-phenyl]-2-ethoxy-acetyl-amino}-methyl)-phenyl]-imino-methyl}-carbamic acid benzyl ester,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-phenethyloxy-phenyl)-2-ethoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(4-cyclopropylmethoxy-2,6-difluoro-phenyl)-2-ethoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-ethoxy-2-(4-ethoxy-2,6-difluoro-phenyl)-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-4-(4-methoxy-phenoxy)-phenyl]-2-ethoxy-acetamide, and
(RS)-N-(4-Carbamimidoyl-benzyl)-2-[4-(3,4-dimethoxy-phenoxy)-2,6-difluoro-phenyl]-2-ethoxy-acetamide hydrochloride, or
a pharmaceutically acceptable salt thereof.

43. The compound according to claim 1, selected from the group consisting of
(RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-4-(3-methoxy-phenoxy)-phenyl]-2-

ethoxy-acetamide hydrochloride,
 (RS)-2-[4-(3-Acetylamino-phenoxy)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-
 2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[4-(4-cyano-phenoxy)-2,6-difluoro-phenyl]-2-
 ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-4-(3-trifluoromethoxy-phenoxy)-
 phenyl]-2-ethoxy-acetamide hydrochloride,
 (RS)-(2,6-Difluoro-4-trifluoromethanesulfonyloxy-phenyl)-ethoxy-acetic acid ethyl ester,
 (RS)-4-(Ethoxy-ethoxycarbonyl-methyl)-3,5-difluoro-benzoic acid 2-trimethylsilanyl-ethyl
 ester,
 (RS)-4-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-3,5-difluoro-N-isobutyl-
 benzamide hydrochloride,
 (RS)-4-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-N-ethyl-3,5-difluoro-
 benzamide hydrochloride,
 (RS)-4-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-3,5-difluoro-N-(2-
 methoxy-ethyl)-benzamide hydrochloride,
 (RS)-4-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-N-cyclopentyl-3,5-difluoro-
 benzamide hydrochloride, and
 (RS)-4-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-3,5-difluoro-N-(2,2,2-
 trifluoro-ethyl)-benzamide hydrochloride, or
 a pharmaceutically acceptable salt thereof.

44. The compound according to claim 1, selected from the group consisting of
 (RS)-4-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-N-cyclopropylmethyl-3,5-
 difluoro-benzamide hydrochloride,
 (RS)-[4-[[2-(2,6-Difluoro-3-hydroxy-phenyl)-2-ethoxy-acetylamino]-methyl]-phenyl]-
 imino-methyl]-carbamic acid benzyl ester,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-hydroxy-phenyl)-2-ethoxy-
 acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-ethoxy-2-{3-[2-(2-ethoxy-ethoxy)-ethoxy]-2,6-
 difluoro-phenyl}-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[3-(3-dimethylamino-propoxy)-2,6-difluoro-
 phenyl]-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-{2-[2-(2-methoxy-ethoxy)-ethoxy]}-
 phenyl)-2-ethoxy-acetamide dihydrochloride,

ethoxy}-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(3-pyridin-4-yl-propoxy)-phenyl]-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(1-methyl-cyclopropylmethoxy)-phenyl]-2-ethoxy-acetamide hydrochloride, and
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(2-piperidin-1-yl-ethoxy)-phenyl]-2-ethoxy-acetamide dihydrochloride, or
 a pharmaceutically acceptable salt thereof.

45. The compound according to claim 1, selected from the group consisting of
 (RS,RS)-N-(4-Carbamimidoyl-benzyl)-2-[3-(3-chloro-2-hydroxymethyl-2-methyl-propoxy)-2,6-difluoro-phenyl]-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-ethoxy-2-[3-(2-ethoxy-ethoxy)-2,6-difluoro-phenyl]-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(2-methoxy-ethoxy)-phenyl]-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[3-(3-dimethylamino-2,2-dimethyl-propoxy)-2,6-difluoro-phenyl]-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(2-thiophen-2-yl-ethoxy)-phenyl]-2-ethoxy-acetamide hydrochloride,
 (RS,RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(tetrahydro-furan-2-ylmethoxy)-phenyl]-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-isobutoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS,RS,RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(2-methyl-cyclopropylmethoxy)-phenyl]-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[3-(2-cyclopropyl-ethoxy)-2,6-difluoro-phenyl]-2-ethoxy-acetamide hydrochloride, and
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-ethoxy-2-(3-ethoxy-2,6-difluoro-phenyl)-acetamide hydrochloride, or
 a pharmaceutically acceptable salt thereof.

46. The compound according to claim 1, selected from the group consisting of
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-propoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-cyclopropylmethoxy-2,6-difluoro-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[3-(2-dimethylamino-ethoxy)-2,6-difluoro-phenyl]-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-cyclobutylmethoxy-2,6-difluoro-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-{2,6-difluoro-3-[2-(2-oxo-pyrrolidin-1-yl)-ethoxy]-phenyl}-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(3,3,3-trifluoro-propoxy)-phenyl]-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(2-pyridin-3-yl-ethoxy)-phenyl]-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-diethylcarbamoylmethoxy-2,6-difluoro-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(2-morpholin-4-yl-ethoxy)-phenyl]-2-ethoxy-acetamide dihydrochloride, and
 (RS,RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(1-methyl-piperidin-3-ylmethoxy)-phenyl]-2-ethoxy-acetamide dihydrochloride, or
 a pharmaceutically acceptable salt thereof.

47. The compound according to claim 1, selected from the group consisting of
 (RS,RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(1-methyl-piperidin-2-ylmethoxy)-phenyl]-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(2-pyridin-2-yl-ethoxy)-phenyl]-2-ethoxy-acetamide dihydrochloride,
 (RS,RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(2-piperidin-2-yl-ethoxy)-phenyl]-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-cyclohexyloxy-2,6-difluoro-phenyl)-2-ethoxy-acetamide hydrochloride,

(RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(piperidin-4-yloxy)-phenyl]-2-ethoxy-acetamide dihydrochloride,
 (R,S)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(4-fluoro-phenoxy)-phenyl]-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(pyridin-3-yloxy)-phenyl]-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(3-trifluoromethyl-phenoxy)-phenyl]-2-ethoxy-acetamide hydrochloride, and
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-m-tolyloxy-phenyl)-2-ethoxy-acetamide hydrochloride, or
 a pharmaceutically acceptable salt thereof.

48. The compound according to claim 1, selected from the group consisting of
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-ethoxy-2-[3-(3-ethoxy-phenoxy)-2,6-difluoro-phenyl]-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-ethoxy-2-[3-(1-ethyl-propoxy)-2,6-difluoro-phenyl]-acetamide acetate,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-cyclopentyloxy-2,6-difluoro-phenyl)-2-ethoxy-acetamide acetate,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(tetrahydro-pyran-4-yloxy)-phenyl]-2-ethoxy-acetamide acetate,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-pyridin-2-yl-phenyl)-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(6-methoxy-pyridin-3-yl)-phenyl]-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-pyridin-3-yl-phenyl)-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-pyrimidin-5-yl-phenyl)-2-ethoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-pyridin-4-yl-phenyl)-2-ethoxy-acetamide dihydrochloride, and
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,4-difluoro-3'-methyl-biphenyl-3-yl)-2-methoxy-acetamide, or
 a pharmaceutically acceptable salt thereof.

49. The compound according to claim 1, selected from the group consisting of
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,4-difluoro-4'-methyl-biphenyl-3-yl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-methoxy-2-(2,4,4'-trifluoro-biphenyl-3-yl)-acetamide acetate,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,4-difluoro-4'-methylsulfanyl-biphenyl-3-yl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,4-difluoro-3'-trifluoromethyl-biphenyl-3-yl)-2-methoxy-acetamide acetate,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,4-difluoro-4'-methoxy-biphenyl-3-yl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(morpholine-4-carbonyl)-phenyl]-2-methoxy-acetamide acetate,
 (RS)-2-[2,6-difluoro-3-(morpholine-4-carbonyl)-phenyl]-N-[4-(N-hydroxycarbamimidoyl)-benzyl]-2-methoxy-acetamide,
 (RS)-3-[(4-Carbamimidoyl-benzylcarbamoyl)-methoxy-methyl]-N-ethyl-2,4-difluoro-benzamide acetate,
 (RS)-3-[(4-Carbamimidoyl-benzylcarbamoyl)-methoxy-methyl]-2,4-difluoro-N-(2-methoxy-ethyl)-benzamide acetate, and
 (RS)-3-[(4-Carbamimidoyl-benzylcarbamoyl)-methoxy-methyl]-N,N-diethyl-2,4-difluoro-benzamide acetate, or
 a pharmaceutically acceptable salt thereof.

50. The compound according to claim 1, selected from the group consisting of
 (RS)-3-[(4-Carbamimidoyl-benzylcarbamoyl)-methoxy-methyl]-2,4-difluoro-N-(2,2,2-trifluoro-ethyl)-benzamide acetate,
 (RS)-3-[(4-Carbamimidoyl-benzylcarbamoyl)-methoxy-methyl]-N-cyclopropylmethyl-2,4-difluoro-benzamide acetate,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(pyridin-2-ylmethoxy)-phenyl]-2-methoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(pyridin-3-ylmethoxy)-phenyl]-2-methoxy-acetamide dihydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(pyridin-4-ylmethoxy)-phenyl]-2-methoxy-acetamide dihydrochloride,

(RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(4-fluoro-phenoxy)-phenyl]-2-methoxy-acetamide acetate,
 (RS)-2-[2,6-difluoro-3-(4-fluoro-phenoxy)-phenyl]-N-[4-(N-hydroxycarbamimidoyl)-benzyl]-2-methoxy-acetamide,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(pyridin-3-yloxy)-phenyl]-2-methoxy-acetamide acetate,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3,5-difluoro-biphenyl-4-yl)-2-methoxy-acetamide hydrochloride, and
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3,5-difluoro-biphenyl-4-yl)-2-ethoxy-acetamide hydrochloride, or
 a pharmaceutically acceptable salt thereof.

51. The compound according to claim 1, selected from the group consisting of
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-4-(1H-indol-5-yl)-phenyl]-2-ethoxy-acetamide acetic acid,
 (RS)-2-(2,6-Difluoro-4-furan-2-yl-phenyl)-2-ethoxy-N-[4-(N-hydroxycarbamimidoyl)-benzyl]-acetamide,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-furan-2-yl-phenyl)-2-ethoxy-acetamide acetate,
 N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-4-(tetrahydro-furan-2-yl)-phenyl]-2-ethoxy-acetamide acetic acid,
 (RS)-{4'-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-3',5'-difluoro-biphenyl-3-yloxy}-acetic acid ethyl ester hydrochloride,
 (RS)-{4'-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-3',5'-difluoro-biphenyl-3-yloxy}-acetic acid,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3'-carbamoylmethoxy-3,5-difluoro-biphenyl-4-yl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[3,5-difluoro-3'-(2-hydroxy-ethoxy)-biphenyl-4-yl]-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[3'-(3-dimethylamino-propoxy)-3,5-difluoro-biphenyl-4-yl]-2-ethoxy-acetamide hydrochloride, and
 (RS)-2-[2'-(2-Benzylloxy-ethoxy)-3,5-difluoro-biphenyl-4-yl]-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride, or
 a pharmaceutically acceptable salt thereof.

52. The compound according to claim 1, selected from the group consisting of
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2'-(2-dimethylamino-ethoxy)-3,5-difluoro-biphenyl-4-yl]-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[3,5-difluoro-2'-(2-hydroxy-ethoxy)-biphenyl-4-yl]-2-ethoxy-acetamide hydrochloride,
 (RS)-{4'-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-3',5'-difluoro-biphenyl-2-yloxy}-acetic acid ethyl ester hydrochloride,
 (RS)-{4'-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-3',5'-difluoro-biphenyl-2-yloxy}-acetic acid,
 (RS)-2-(2'-Carbamoylmethoxy-3,5-difluoro-biphenyl-4-yl)-2-ethoxy-N-[4-(N-hydroxycarbamimidoyl)-benzyl]-acetamide,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2'-carbamoylmethoxy-3,5-difluoro-biphenyl-4-yl)-2-ethoxy-acetamide acetate,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-pyridin-4-yl-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-pyrimidin-5-yl-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-pyrimidin-2-yl-phenyl)-2-ethoxy-acetamide hydrochloride, and
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-pyridin-2-yl-phenyl)-2-ethoxy-acetamide hydrochloride, or
 a pharmaceutically acceptable salt thereof.

53. The compound according to claim 1, selected from the group consisting of
 (RS)-2-[4-(2-Amino-pyrimidin-5-yl)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-pyridin-3-yl-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-2-[4-(6-Amino-pyridin-2-yl)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-2-[4-(5-Amino-pyridin-2-yl)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-4'-[(4-Carbamimidoyl-benzylcarbamoyl)-ethoxy-methyl]-3',5'-difluoro-biphenyl-3-

carboxylic acid methyl ester hydrochloride,
 (RS)-(2-[4-(6-Amino-pyridin-3-yl)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-4'-[(4-Carbamidoyl-benzylcarbamoyl)-ethoxy-methyl]-3',5'-difluoro-biphenyl-3-carboxylic acid,
 (RS){Amino-[4-({2-[4-(6-amino-pyridin-3-yl)-2,6-difluoro-phenyl]-2-ethoxy-acetyl-amino}-methyl)-phenyl]-methylene}-carbamic acid ethyl ester,
 (RS)-2-[4-(6-Amino-pyridin-3-yl)-2,6-difluoro-phenyl]-2-ethoxy-N-[4-(N-hydroxycarbamidoyl)-benzyl]-acetamide, and
 (RS)-N-(4-Carbamidoyl-benzyl)-2-(3,5-difluoro-2'-hydroxymethyl-biphenyl-4-yl)-2-ethoxy-acetamide hydrochloride, or
 a pharmaceutically acceptable salt thereof.

54. The compound according to claim 1, selected from the group consisting of
 (RS)-N-(4-Carbamidoyl-benzyl)-2-(2'-chloromethyl-3,5-difluoro-biphenyl-4-yl)-2-ethoxy-acetamide,
 (RS)-2-[3,5-Difluoro-2'-(hydroxyimino-methyl)-biphenyl-4-yl]-2-ethoxy-N-[4-(N-hydroxycarbamidoyl)-benzyl]-acetamide,
 (RS)-2-(2'-Aminomethyl-3,5-difluoro-biphenyl-4-yl)-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide acetate,
 (RS)-N-(4-Carbamidoyl-benzyl)-2-(2-fluoro-4-methoxy-3-phenoxy-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-carbamimidoyl-benzyl)-2-(2-ethynyl-6-fluoro-phenyl)-2-methoxy-acetamide hydrochloride according,
 (RS)-N-(4-Carbamidoyl-benzyl)-2-(2-ethyl-6-fluoro-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamidoyl-benzyl)-2-[2-fluoro-6-(3-hydroxy-prop-1-ynyl)-phenyl]-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamidoyl-benzyl)-2-[2-fluoro-6-(3-hydroxy-propyl)-phenyl]-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamidoyl-benzyl)-2-(3-fluoro-biphenyl-2-yl)-2-methoxy-acetamide hydrochloride, and
 (RS)-2-(3'-Amino-3-fluoro-biphenyl-2-yl)-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide hydrochloride, or

a pharmaceutically acceptable salt thereof.

55. The compound according to claim 1, selected from the group consisting of
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-fluoro-3'-nitro-biphenyl-2-yl)-2-methoxy-acetamide hydrochloride,
(RS)-2-[2-(6-Amino-pyridin-2-yl)-6-fluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide acetate,
(RS)-{2-[(4-Carbamimidoyl-benzylcarbamoyl)-methoxy-methyl]-3-fluoro-phenoxy}-acetic acid methyl ester acetate,
(RS)-{2-[(4-Carbamimidoyl-benzylcarbamoyl)-methoxy-methyl]-3-fluoro-phenoxy}-acetic acid,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-[2-(3-dimethylamino-propoxy)-6-fluoro-phenyl]-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2-fluoro-6-phenoxy-phenyl)-2-methoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
(RS)-2-(4-Benzoyloxy-2,6-difluoro-phenyl)-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-isopropoxy-phenyl)-2-ethoxy-acetamide hydrochloride, and
(RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-4-(pyridin-2-ylmethoxy)-phenyl]-2-ethoxy-acetamide hydrochloride, or
a pharmaceutically acceptable salt thereof.

56. The compound according to claim 1, selected from the group consisting of
(RS)-2-[2,6-Difluoro-4-(pyridin-2-ylmethoxy)-phenyl]-2-ethoxy-N-[4-(N-hydroxycarbamimidoyl)-benzyl]-acetamide,
(RS)-{Amino-[4-({2-[2,6-difluoro-4-(pyridin-2-ylmethoxy)-phenyl]-2-ethoxy-acetyl-amino}-methyl)-phenyl]-methylene}-carbamic acid ethyl ester,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-4-(pyridin-3-ylmethoxy)-phenyl]-2-ethoxy-acetamide hydrochloride,
(RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-4-(pyridin-4-ylmethoxy)-phenyl]-2-ethoxy-acetamide hydrochloride,

(RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-phenoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-4-(pyridin-3-yloxy)-phenyl]-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-isopropoxy-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(3-carbamoylmethoxy-2,6-difluoro-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-2-[3-(2-Benzylloxy-ethoxy)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride, and
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-3-(2-hydroxy-ethoxy)-phenyl]-2-ethoxy-acetamide hydrochloride, or
 a pharmaceutically acceptable salt thereof.

57. The compound according to claim 1, selected from the group consisting of
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-phenoxy-phenyl)-2-ethoxy-acetamide acetate,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,4-difluoro-biphenyl-3-yl)-2-ethoxy-acetamide hydrochloride,
 (RS)-2-(2,6-Difluoro-3-phenylamino-phenyl)-N-[4-(N-hydroxycarbamimidoyl)-benzyl]-2-methoxy-acetamide,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-phenylamino-phenyl)-2-methoxy-acetamide acetate,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-isopropylamino-phenyl)-2-methoxy-acetamide acetate,
 (RS)-2-(3-Acetylamino-2,6-difluoro-phenyl)-N-(4-carbamimidoyl-benzyl)-2-methoxy-acetamide hydrochloride,
 (RS)-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-phenylacetylamino-phenyl)-2-methoxy-acetamide hydrochloride,
 (RS)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-3-hydroxymethyl-phenyl)-2-ethoxy-acetamide hydrochloride,
 (RS)-2-[3-(Acetylamino-methyl)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide hydrochloride, and

(RS)-2-(3-Aminomethyl-2,6-difluoro-phenyl)-N-(4-carbamimidoyl-benzyl)-2-ethoxy-acetamide acetic acid, or
a pharmaceutically acceptable salt thereof.

58. The compound according to claim 1, selected from the group consisting of
(RS)-(4-Carbamidoyl-benzyl)-2-(2,6-difluoro-3-phenylaminomethyl-phenyl)-2-ethoxy-acetamide hydrochloride,
(RS)-(4-Carbamidoyl-benzyl)-2-(2,6-difluoro-3-morpholin-4-ylmethyl-phenyl)-2-ethoxy-acetamide hydrochloride,
(RS)-(4-Carbamidoyl-benzyl)-2-(2,6-difluoro-3-piperidin-1-ylmethyl-phenyl)-2-ethoxy-acetamide hydrochloride,
(RS)-2-(3-Diethoxymethyl-2,6-difluoro-phenyl)-2-ethoxy-N-[4-(N-hydroxycarbamidoyl)-benzyl]-acetamide,
(RS)-(4-Carbamidoyl-benzyl)-2-(2,6-difluoro-3-formyl-phenyl)-2-ethoxy-acetamide acetic acid (1:4),
(RS)-N-(4-Carbamidoyl-2,6-difluoro-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-ethoxy-acetamide; hydrochloride,
(RS)-N-(4-Carbamidoyl-2,6-difluoro-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide acetate,
(RS)-N-(4-Carbamidoyl-2,6-difluoro-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide acetate, and
(RS)-N-(4-Carbamidoyl-2,6-difluoro-benzyl)-2-(2-fluoro-4-methoxy-phenyl)-2-methoxy-acetamide acetate, or
a pharmaceutically acceptable salt thereof.

59. The compound according to claim 1, selected from the group consisting of
(RS)-[4-Carbamidoyl-2-(carbamoylmethyl-amino)-benzyl]-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
(RS)-N-(2-Benzylamino-4-carbamimidoyl-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide acetate,
(RS)-[4-Carbamidoyl-2-(2-fluoro-benzylamino)-benzyl]-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
(RS)-[4-Carbamidoyl-2-[(pyridin-2-ylmethyl)-amino]-benzyl]-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,


(RS)-[4-Carbamimidoyl-2-(4-chloro-2-fluoro-benzylamino)-benzyl]-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
 (RS)-(4-Carbamimidoyl-2-phenethylamino-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
 (RS)-(5-Carbamimidoyl-2-[[2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetylamino]-methyl]-phenylamino)-acetic acid ethyl ester hydrochloride,
 (RS)-(5-Carbamimidoyl-2-[[2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetylamino]-methyl]-phenylamino)-acetic acid acetate,
 (RS)-(4-Carbamimidoyl-2-phenylmethanesulfonylamino-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride, and
 (RS)-[2-(3-Benzyl-ureido)-4-carbamimidoyl-benzyl]-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide acetate, or
 a pharmaceutically acceptable salt thereof.

60. The compound according to claim 1, selected from the group consisting of
 (RS)-(5-Carbamimidoyl-2-[[2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetylamino]-methyl]-phenyl)-carbamic acid benzyl ester hydrochloride,
 (RS)-(4-Carbamimidoyl-2-phenylamino-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide hydrochloride,
 (RS)-2-[4-(6-Amino-pyridin-3-yl)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-2-carbamoylmethoxy-benzyl)-2-ethoxy-acetamide hydrochloride acetic acid (1:1:2),
 (RS)-(4-Carbamimidoyl-2-carbamoylmethoxy-benzyl)-2-[2,6-difluoro-4-(pyridin-2-ylmethoxy)-phenyl]-2-ethoxy-acetamide hydrochloride,
 (RS)-2-[4-(6-Amino-pyridin-3-yl)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-2,6-difluoro-benzyl)-2-ethoxy-acetamide acetate,
 (RS)-[(4-[[2-(2,6-Difluoro-4-methoxy-phenyl)-2-methoxy-acetylamino]-methyl]-phenyl)-imino-methyl]-carbamic acid tert-butyl ester,
 (S)-[(4-[[2-(2,6-Difluoro-4-methoxy-phenyl)-2-methoxy-acetylamino]-methyl]-phenyl)-imino-methyl]-carbamic acid tert-butyl ester,
 (R)-[(4-[[2-(2,6-Difluoro-4-methoxy-phenyl)-2-methoxy-acetylamino]-methyl]-phenyl)-imino-methyl]-carbamic acid tert-butyl ester,
 (S)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide formate, and

(R)-N-(4-Carbamimidoyl-benzyl)-2-(2,6-difluoro-4-methoxy-phenyl)-2-methoxy-acetamide formiate, or
a pharmaceutically acceptable salt thereof.

61. The compound according to claim 1, selected from the group consisting of
[1-Amino-1-(4-{{(R)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetylamino}-methyl}-phenyl)-meth-(E)-ylidene]-carbamic acid benzyl ester,
(R)-N-(4-Carbamimidoyl-benzyl)-2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetamide acetate,
(RS)-[Amino-(4-{{2-ethoxy-2-(2-fluoro-4-methoxy-phenyl)-acetylamino}-methyl}-phenyl)-methylene]-carbamic acid benzyl ester,
(RS)-[(4-{{2-(2,6-Difluoro-4-methoxy-phenyl)-2-methoxy-acetylamino}-methyl}-phenyl)-imino-methyl]-carbamic acid benzyl ester,
(RS)- N-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-4-(1-oxy-pyridin-4-yl)-phenyl]-2-methoxy-acetamide hydrochloride,
(RS)-(4-Carbamimidoyl-benzyl)-2-[2,6-difluoro-4-(tetrahydro-pyran-4-yl)-phenyl]-2-ethoxy-acetamide acetate, and
(RS)-(4-Carbamimidoyl-benzyl)-2-(4-cyclohexyl-2,6-difluoro-phenyl)-2-ethoxy-acetamide acetate, or
a pharmaceutically acceptable salt thereof.

62. A process for the manufacture of compounds of formula (I) as defined in claim 1, which process comprises converting the nitrile group in a compound of formula (II)




(II)

wherein R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , X and Y are defined in claim 1, into a carbamimidoyl group, or into a N-hydroxy-carbamimidoyl group, or into a N-amino-carbamimidoyl group.

63. The process according to claim 62 in which further comprises converting the resulting compound into a pharmaceutically acceptable salt.

64. A compound of formula (II)



(II)

wherein R^2 , R^3 and R^4 independently from each other are selected from the group consisting of hydrogen, halogen, hydroxy, carboxy-lower-alkyl-NH, carbamoyl-lower-alkyl-NH, lower-alkoxy-carbonyl-lower-alkyl-NH, hydroxy-cycloalkyl-oxy, dihydroxy-cycloalkyl-oxy, aryl, aryloxy, aryl-NH, aryl-lower-alkyl-NH, aryl-lower-alkyl-SO₂-NH, aryl-lower-alkoxy-carbonyl-NH, aryl-lower-alkyl-NH-carbonyl-NH, heteroaryloxy, heteroaryl-lower-alkyl-NH, lower-alkoxy, and lower-alkoxy substituted with hydroxy, carboxy, carbamoyl, carbamimidoyl, CF₃, aryl, heteroaryl, lower-alkyl-carbamoyl, lower-alkoxy-carbonyl, aryl-carbamoyl, lower-alkoxy-lower-alkyl-carbamoyl, heterocyclyl-lower-alkyl-carbamoyl, or N(lower-alkyl)₂-lower-alkyl-carbamoyl;

R^5 is lower-alkyl or cycloalkyl, or, if X is O or NR¹², R^5 is lower alkyl, cycloalkyl or hydrogen;

R^6 is hydrogen, lower-alkyl, or fluoro-lower-alkyl;

Y is N or C-R¹¹;

R^7 , R^8 , R^9 , R^{10} and R^{11} independently from each other are selected from the group consisting of hydrogen, hydroxy, halogen, amino, lower-alkyl-amino, di-lower-alkyl-amino, lower-alkyl-carbonyl-amino, NO₂, fluoro-lower-alkyl, lower-alkoxy, hydroxy-lower-alkoxy, fluoro-lower-alkoxy, lower-alkinyl, hydroxy-lower-alkinyl, aryl, aryl-lower-alkoxy, aryloxy, aryloxy-lower-alkoxy, heterocyclyl, heterocycliloxy, lower-alkoxy-carbonyl-lower-alkoxy, carbamoyl-lower-alkoxy, carboxy-lower-alkoxy, cycloalkyloxy, heteroaryl, amino-lower-alkoxy, lower-alkyl-amino-lower-alkoxy, and di-lower-alkyl-amino-lower-alkoxy, lower-alkyl-carbonyl-amino-lower-alkyl, HO-N=CH, HCO, fluoro-lower-alkyl-SO₂-O, (lower-alkoxy)₂₋₄, CH(lower-alkoxy)₂, hydroxy-chloro-lower-alkoxy, aryl-lower-alkoxy-lower-alkoxy, aryl-NH, aryl-NH-lower-alkyl, aryl-lower-alkyl-carbonyl-NH, heterocyclyl-lower-alkyl, heterocyclyl-carbonyl, heterocyclyl-lower-alkoxy, lower-alkyl-carbamoyl, fluoro-lower-alkyl-carbamoyl, cycloalkyl-carbamoyl, cycloalkyl-lower-alkyl-carbamoyl, di-lower-alkyl-carbamoyl, lower-alkoxy-lower-alkyl-carbamoyl, di-lower-alkyl-carbamoyl-lower-alkoxy, heteroaryloxy, heteroaryl-lower-alkoxy, amino-lower-alkyl, lower-alkyl, hydroxy-lower-alkyl, cycloalkyl, cycloalkyl-lower-alkoxy, and cycloalkyl-lower-alkoxy substituted with lower-alkyl;

or

R^8 and R^9 or R^8 and R^7 are bound to each other to form a ring together with the carbon atoms to which they are attached and R^8 and R^9 together or R^8 and R^7 together are -O-CH₂-O-, -O-CH₂-CO-NH-, -O-CH₂-CH₂-CH₂-, -CH=CH-CH=CH-, or -CH=CH-

CH=CH- substituted with lower-alkyl or lower-alkoxy, and R¹⁰, R¹¹ and R⁷ or R⁹ respectively are as defined above;

X is O, S, NR¹², or SO₂;

R¹² is hydrogen, lower-alkyl, or lower-alkyl-carbonyl..

65. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or adjuvant.

66. A method for the therapeutic or prophylactic treatment of a patient suffering from a disease which is associated with the formation of clotting factors Xa, IXa and thrombin induced by factor VIIa and tissue factor, which method comprises administering a therapeutically effective amount of a compound according to claim 1 to a human being or animal.

67. A method for the therapeutic or prophylactic treatment of a disease which is associated with arterial and venous thrombosis, deep vein thrombosis, pulmonary embolism, unstable angina pectoris, cardiac infarction, stroke due to atrial fibrillation, inflammation, arteriosclerosis or tumor, which method comprises administering a therapeutically effective amount of a compound according to claim 1 to a human being or animal.